Subtyping anti-infliximab antibodies by the homogenous mobility shift assay (HMSA): potential utility in a pharmacokinetic case study

Pathology. 2023 Jun;55(4):587-590. doi: 10.1016/j.pathol.2022.08.013. Epub 2022 Oct 31.

Authors

Ke Li Chow¹, Paula Elizabeth Keating², John Liston O'Donnell²

Affiliations

¹ Department of Immunology, Canterbury Health Laboratories, Christchurch, New Zealand. Electronic address: [email protected].
² Department of Immunology, Canterbury Health Laboratories, Christchurch, New Zealand.

PMID: 36400595
DOI: 10.1016/j.pathol.2022.08.013

No abstract available

Publication types

Letter

MeSH terms

Antibodies*
Crohn Disease*
Electrophoretic Mobility Shift Assay
Enzyme-Linked Immunosorbent Assay
Humans
Infliximab / therapeutic use

Substances

Infliximab
Antibodies